IONS (Ionis Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IONS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | C FRANK BENNETT | EVP, Chief Scientific Officer | J | — | — |
| 2026-09-02 | Brian Birchler | EVP, Corp and Development Ops | J | — | — |
| 2026-09-02 | PATRICK R. O'NEIL | EVP CLO & General Counsel | J | — | — |
| 2026-09-02 | Brett P Monia | Chief Executive Officer | J | — | — |
| 2026-07-31 | Michael R Hayden | Director | Buy | — | — |
| 2026-07-17 | LUDWIG HANTSON | Director | A | — | — |
| 2026-07-17 | Peter N Reikes | Director | A | — | — |
| 2026-07-17 | JOAN E HERMAN | Director | M | — | — |
| 2026-07-17 | SPENCER R BERTHELSEN | Director | M | — | — |
| 2026-07-09 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sell | — | — |
| 2026-07-09 | Allene M. Diaz | Director | MIXED | — | — |
| 2026-07-09 | C FRANK BENNETT | EVP, Chief Scientific Officer | MIXED | — | — |
| 2026-07-06 | SPENCER R BERTHELSEN | Director | A | — | — |
| 2026-07-06 | JOAN E HERMAN | Director | A | — | — |
| 2026-07-06 | Michael R Hayden | Director | A | — | — |
| 2026-07-06 | JOSEPH LOSCALZO | Director | A | — | — |
| 2026-07-06 | MICHAEL J. YANG | Director | A | — | — |
| 2026-07-06 | JOSEPH KLEIN III | Director | MIXED | — | — |
| 2026-07-06 | Allene M. Diaz | Director | A | — | — |
| 2026-06-26 | Brett P Monia | Chief Executive Officer | MIXED | — | — |
| 2026-06-26 | Eric Swayze | EVP Research | Sell | — | — |
| 2026-06-16 | SPENCER R BERTHELSEN | Director | MIXED | — | — |
| 2026-06-16 | Holly B. Kordasiewicz | EVP, Chief Development Officer | MIXED | — | — |
| 2026-06-08 | Peter N Reikes | Director | A | — | — |
| 2026-06-08 | LUDWIG HANTSON | Director | A | — | — |
| 2026-06-03 | SPENCER R BERTHELSEN | Director | MIXED | — | — |
| 2026-05-15 | Brett P Monia | Chief Executive Officer | MIXED | — | — |
| 2026-05-06 | JOSEPH LOSCALZO | Director | MIXED | — | — |
| 2026-05-05 | JOSEPH KLEIN III | Director | MIXED | — | — |
| 2026-04-30 | Joseph Baroldi | EVP, Chief Business Officer | Sell | — | — |
| 2026-04-17 | Joseph Baroldi | EVP, Chief Business Officer | MIXED | — | — |
| 2026-04-17 | Brian Birchler | EVP, Corp and Development Ops | MIXED | — | — |
| 2026-04-17 | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | MIXED | — | — |
| 2026-04-17 | B LYNNE PARSHALL | Director | Sell | — | — |
| 2026-04-02 | Shannon L. Devers | EVP, Chief Human Resources Ofc | Sell | — | — |
| 2026-04-02 | JOSEPH KLEIN III | Director | MIXED | — | — |
| 2026-03-23 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sell | — | — |
| 2026-03-18 | ELIZABETH L HOUGEN | EVP, Finance & CFO | MIXED | — | — |
| 2026-03-11 | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | MIXED | — | — |
| 2026-03-11 | Brett P Monia | Chief Executive Officer | MIXED | — | — |
| 2026-03-11 | PATRICK R. O'NEIL | EVP CLO & General Counsel | Sell | — | — |
| 2026-03-05 | Joseph Baroldi | EVP, Chief Business Officer | MIXED | — | — |
| 2026-03-05 | C FRANK BENNETT | EVP, Chief Scientific Officer | MIXED | — | — |
| 2026-03-05 | Shannon L. Devers | EVP, Chief Human Resources Ofc | MIXED | — | — |
| 2026-03-05 | Allene M. Diaz | Director | MIXED | — | — |
| 2026-03-05 | JOSEPH KLEIN III | Director | MIXED | — | — |
| 2026-03-05 | JOSEPH LOSCALZO | Director | MIXED | — | — |
| 2026-03-03 | C FRANK BENNETT | EVP, Chief Scientific Officer | J | — | — |
| 2026-03-03 | Brian Birchler | EVP, Corp and Development Ops | J | — | — |
| 2026-03-03 | Brett P Monia | Chief Executive Officer | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Exec Chairman of the Board | 496,412 | — |
| — | EVP, Finance & CFO | 254,221 | — |
| — | Chief Executive Officer | 242,760 | — |
| — | Director | 161,303 | — |
| — | EVP, Corp and Development Ops | 102,883 | — |
| — | EVP, Chief Development Officer | 77,957 | — |
| — | Director | 73,298 | — |
| — | EVP, Chf Clinical Develop Ofcr | 63,890 | — |
| — | EVP, Chief Scientific Officer | 60,128 | — |
| — | EVP CLO & General Counsel | 59,205 | — |
| — | Director | 58,432 | — |
| — | Director | 52,035 | — |
| — | Director | 51,344 | — |
| — | Director | 51,306 | — |
| — | EVP, Chief Business Officer | 49,256 | — |
| — | Director | 47,298 | — |
| — | EVP,Chf GL Pdt Str & Oper Ofc | 35,788 | — |
| — | EVP, Chf GL Pdt Str Ofcr | 28,615 | — |
| — | Director | 22,633 | — |
| — | EVP, Chief Development Officer | 22,096 | — |
| — | EVP Research | 22,077 | — |
| — | Director | 18,516 | — |
| — | EVP, Chief Human Resources Ofc | 16,348 | — |
| — | Director | 14,222 | — |
| — | Chief Business Officer | 11,127 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IONS quote page; the site-wide leaderboard is on the insider transactions hub.